This system enables precise, parallel manipulation of thousands of nanoliter-scale cell cultures, advancing tissue engineering and high-throughput drug screening.

This financing will support expanded placements of GPB’s Curate™ Cell Processing System into partner facilities to enable optimized development and manufacturing in CAR-T and TCR programs, as ...

Parallel Bio raises $21 million in Series A funding and completes first preclinical trial from immune organoid platform with Centivax.